Nigeria: WHO Recommends a Clinical Trial of Ebola Vaccine Against Bundibugyo Virus

[Premium Times] The recommendation followed preliminary animal study data suggesting that the vaccine may provide some cross-protection against the disease, particularly in reducing deaths.

The recommendation followed preliminary animal study data suggesting that the vaccine may provide some cross-protection against the disease, particularly in reducing deaths.

The Bundibugyo epidemic, ​the world's second-largest, has been described as the ⁠fastest-spreading on record.

Trials for new Ebola vaccines are now underway in Canada and the UK but the World Health Organization (W.H.O.) said Tuesday volunteers are needed to participate in clinical experiments as deaths and cases soar in the largest ever outbreak on record in the Democratic Republic of the Congo (DRC).

Novo and Lilly earnings are out, Aurora Therapeutics slashing staff, and more biotech news from The Readout

Moderna has vaccinated the first participants in a trial for a Bundibugyo Ebola vaccine, as the Democratic Republic of Congo continues to battle its fastest-growing outbreak on record.

The vaccine relies on the same mRNA technology used in the pharmaceutical company's Covid-19 vaccine

DR Congo's Ebola outbreak has killed 1,707 people since May. With no approved vaccine for the Bundibugyo strain, the WHO is accelerating trials as Ituri's cases climb.

The vaccine relies on the same mRNA technology used in Moderna’s Covid-19 vaccine.

Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against Bundibugyo ebolavirus, a strain of Ebola that has killed more than 1,650 people so far and currently has no approved vaccine.

Trial will run at three sites in Canada and aims to enroll about 80 healthy adults